Hepatobiliary Cancers: Translational Advances and Molecular Medicine

1. Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-epidemiological Contexts
Yujin Hoshida, Naoto Kubota, Naoto Fujiwara
2. Inflammatory Pathways and Hepatobiliary Cancer Risk Mechanisms and Prevention
Mario Strazzabosco and Massimiliamo Cadamuro
3. Causes and Functional Intricacies of Inter- and Intratumor Heterogeneity in Primary Liver Cancers
Xin Wei Wang and Subreen Khatib
4. Implication of Genetic Heterogeneity in Hepatocellular Cancer
Renumathy Dhanasekaran
5. Understanding the Genetic Basis for Cholangiocarcinoma
Lewis R. Roberts and Mikayla A. Schmidt
6. Novel Insights into Molecular and Immune Subtypes of Intrahepatic Cholangiocarcinoma
Daniela Sia and Emily Bramel
7. Cancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma Progression and Therapeutic Resistance
Silvia Affo, Aashreya Ravichandra, Sonakshi Bhattacharjee
8. Mechanisms and Clinical Significance of TGF-ss in Hepatobiliary Cancer Progression
Lopa Mishra and Zobia Zaidi
9. Matricellular proteins in intrahepatic cholangiocarcinoma
Alphonse Eugene Sirica
10. Yap Activation and Hippo Pathway Signaling in the Pathogenesis and Prognosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Satdarshan (Paul) Singh Monga, Sungjin Ko, Yuhua Xue, George K. Michalopoulos,
11. Patient-derived Functional Organoids as a Personalized Approach for Drug Screening Against Hepatobiliary Cancers
Florin M. Selaru and Ling Li
12. Molecular Therapeutic Targets for Cholangiocarcinoma: Present Challenges and Future Possibilities
Jesper B. Andersen, Colm J. O'Rourke, Dan Hogdall
13. Immunotherapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Current and Developing Strategies
Bruno Sangro and Josepmaria Argemi
14. Immunotherapy for Hepatobiliary Cancers: Emerging Targets and Translational Advances
Mitchell Ho, Dan Li, Shaoli Lin, Jessica Hong

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Imunologia
• Genética (não médica)
• Virologia (não médica)
• Biologia Celular (citologia)

Bile duct tumors; Cancer patient-derived organoids; Cancer-associated fibroblasts (CAFs); CAR-T; Cholangiocarcinogenesis; Cholangiocarcinoma; Cholangiocarcinoma (CCA); Cholangiocarcinoma progression; Cirrhosis; Clinical trials; Congenital hepatic fibrosis; Desmoplastic reaction; Drug screening; Epithelial-mesenchymal transition; Expression profiling; Fluke infestations; Gallbladder cancer; Genome wide association studies; Genomic landscape; Genomics; Germline mutations; Glypican-3; Hepatobiliary cancer; Hepatocellular carcinoma; Hepatocyte; Heterogeneity; Hippo signaling; Immune checkpoint inhibitor; Immunotherapy; Immunotherapy hepatocellular carcinoma; Integrative omics; Intrahepatic cholangiocarcinoma; Intrahepatic cholangiocarcinoma (iCCA); Liver cancer; Liver cancer etiologies; Liver disease; Mesothelin; Metastatic niche; Molecular classes; Next generation sequencing; Next-generation sequencing; Osteopontin; Pathogenic germline alterations studies; Patient stratification; Periostin; Precision medicine; Predictive biomarkers; Primary sclerosing cholangitis; Progenitor; Prognostic biomarkers; Single nucleotide polymorphisms; Spatial architecture; Stem cell; Stratification; Targeted therapy; Taz; Tenascin-C; Therapeutic resistance; Therapeutic targeting; Therapeutic targets; Thrombospondin-1; Transcriptomics; Transdifferentiation; Transforming growth factor ss; Transforming growth factor-ss; Tumor evolution; Tumor heterogeneity; Tumor immunology; Tumor metabolism; Tumor microenvironment; Tumor microenvironment (TME); Tumor stroma; Virtual microdissection; YAP1